Lenalidomide
Treatment for Multiple Myeloma
Typical Dosage: 5-25 mg orally daily for 21 days of a 28-day cycle
Effectiveness
85%
Safety Score
55%
Clinical Trials
599
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
5-25 mg orally daily for 21 days of a 28-day cycle
Time to Effect
1-3 months
Treatment Duration
Years to lifetime
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120,000
Monitoring:$7,500
Side Effect Mgmt:$10,000
Total Annual:$137,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$100,000/QALY
QALYs Gained
2
Outcome-Based Costs
Cost per Responder
$183,333
Cost per Remission
$343,750
Comparison vs Bortezomib + Dexamethasone
Cost Difference
+$30,000/year
More expensive
QALY Difference
+0.92 QALYs
Better outcomes
Dominance
No dominance
Lenalidomide Outcomes
for Multiple Myeloma
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+75%
Remission Rate
+40%
Common Side Effects
Myelosuppression (Neutropenia, Thrombocytopenia)
+60%
Fatigue
+50%
Diarrhea/Constipation
+40%
Rash
+30%
Thromboembolism (DVT/PE)
+15%
Sources:
Active Clinical Trials
3 active trials recruiting for Lenalidomide in Multiple Myeloma
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
NCT05091372RECRUITINGPHASE2
94 participants
INTERVENTIONAL
Houston, United States
Started: Dec 1, 2022
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
NCT03106324ACTIVE NOT RECRUITING
911 participants
OBSERVATIONAL
Innsbruck, Austria +124 more
Started: Mar 31, 2017
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
NCT04009109ACTIVE NOT RECRUITINGPHASE2
79 participants
INTERVENTIONAL
Bangor, United States +6 more
Started: Oct 21, 2020
Completed Clinical Trials
14 completed trials for Lenalidomide in Multiple Myeloma
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
NCT00622336COMPLETEDPHASE3
330 participants
INTERVENTIONAL
Izhevsk, Russia +6 more
Started: Apr 1, 2003
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT00065351COMPLETEDPHASE2
222 participants
INTERVENTIONAL
Glendale, United States +25 more
Started: Jul 1, 2003
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
NCT00091624COMPLETEDPHASE1
77 participants
INTERVENTIONAL
Cleveland, United States
Started: Mar 1, 2003
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
NCT00153933COMPLETEDPHASE1
58 participants
INTERVENTIONAL
Tampa, United States +5 more
Started: Aug 1, 2004
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
NCT00056160COMPLETEDPHASE3
353 participants
INTERVENTIONAL
Hoover, United States +48 more
Started: Jan 1, 2003
A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan
NCT01752075COMPLETED
100 participants
OBSERVATIONAL
Taipei, Taiwan
Started: Jan 1, 2011
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
NCT00051116COMPLETEDPHASE2
100 participants
INTERVENTIONAL
Little Rock, United States
Started: May 1, 2002
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
NCT01621672COMPLETEDPHASE3
42 participants
INTERVENTIONAL
Little Rock, United States
Started: Apr 1, 2010
Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma
NCT00396045COMPLETEDPHASE1, PHASE2
54 participants
INTERVENTIONAL
Brescia, Italy +8 more
Started: Jan 1, 2005
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
NCT00891384COMPLETEDPHASE3
194 participants
INTERVENTIONAL
Heidelberg, Germany +4 more
Started: Apr 1, 2009
Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma
NCT01450215COMPLETEDPHASE2
62 participants
INTERVENTIONAL
Stockholm, Sweden +1 more
Started: Mar 1, 2011
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01402284COMPLETEDPHASE2
45 participants
INTERVENTIONAL
Bethesda, United States
Started: Jul 21, 2011
Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma
NCT00778752COMPLETEDPHASE1, PHASE2
24 participants
INTERVENTIONAL
Hamburg, Germany +1 more
Started: Apr 1, 2009
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
NCT00847639COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Duarte, United States +7 more
Started: Feb 1, 2009
Showing 20 of 604 total trials